Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

被引:282
作者
Contos, MJ
Cales, W
Sterling, RK
Luketic, VA
Shiffman, ML
Mills, AS
Fisher, RA
Ham, J
Sanyal, AJ
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol Hepatol Nutr, Dept Internal Med, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol Hepatol Nutr, Dept Pathol, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol Hepatol Nutr, Dept Surg, Richmond, VA 23298 USA
关键词
D O I
10.1053/jlts.2001.23011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Many subjects with cryptogenic cirrhosis have underlying nonalcoholic steatohepatitis (NASH), The natural history of NASH-related cryptogenic cirrhosis after orthotopic liver transplantation (OLT) is not well defined. A primarily retrospective study of patients with the clinical histological phenotype of NASH-related cirrhosis undergoing OLT was performed. Data were compared with 2 sets of age- and weight-matched controls with (1) primary biliary cirrhosis or primary sclerosing cholangitis or (2) alcoholic liver disease. After OLT, all patients were managed by a standard immunosuppressive protocol. Liver biopsies were performed at 6 and 12 months after OLT and at 1- to 2-year intervals thereafter, as well as when liver enzyme levels were elevated enough to warrant diagnostic biopsy. Twenty-seven subjects with cryptogenic cirrhosis and a clinical histological phenotype of NASH and 3 patients with a long-standing diagnosis of NASH before OLT were included. The 30-day perioperative mortality was 1 in 30 patients, During a median follow-up of 3.5 +/- 2.7 years, 2 additional patients died of sepsis, There was a time-dependent increase in the risk for allograft steatosis that approached 100% by 5 years compared with only an approximately 25% incidence of steatosis in the control groups (P < .009, log-rank test). On multivariate analysis, only the cumulative steroid dose correlated with time to development of allograft steatosis, Three patients developed histological progression from hepatic steatosis to steatohepatitis, Of these, 1 patient developed progressive fibrosis. Four patients experienced at least 1 episode of acute cellular rejection; however, no patient developed chronic rejection or graft failure. In conclusion, nonalcoholic fatty liver disease occurs frequently after OLT in patients with the phenotype of NASH-related cirrhosis. Despite the frequent histological recurrence of disease, clinical outcomes are similar to those of other groups of patients undergoing OLT.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 49 条
  • [1] FATTY LIVER HEPATITIS AND CIRRHOSIS IN OBESE PATIENTS
    ADLER, M
    SCHAFFNER, F
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 67 (05) : 811 - 816
  • [2] HEPATIC-EFFECTS OF DIETARY WEIGHT-LOSS IN MORBIDLY OBESE SUBJECTS
    ANDERSEN, T
    GLUUD, C
    FRANZMANN, MB
    CHRISTOFFERSEN, P
    [J]. JOURNAL OF HEPATOLOGY, 1991, 12 (02) : 224 - 229
  • [3] Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
    Angulo, P
    Keach, JC
    Batts, KP
    Lindor, KD
    [J]. HEPATOLOGY, 1999, 30 (06) : 1356 - 1362
  • [4] [Anonymous], 2000, Cleve Clin J Med
  • [5] NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY
    BACON, BR
    FARAHVASH, MJ
    JANNEY, CG
    NEUSCHWANDERTETRI, BA
    [J]. GASTROENTEROLOGY, 1994, 107 (04) : 1103 - 1109
  • [6] AMYLIN/INSULIN SECRETORY RATIOS IN MORBIDLY OBESE MAN - INVERSE RELATIONSHIP WITH GLUCOSE DISAPPEARANCE RATE
    BLACKARD, WG
    CLORE, JN
    KELLUM, JM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (05) : 1257 - 1260
  • [7] Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
    Bonkovsky, HL
    Jawaid, Q
    Tortorelli, K
    LeClair, P
    Cobb, J
    Lambrecht, RW
    Banner, BF
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 (03) : 421 - 429
  • [8] Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity?
    Brunt, EM
    [J]. LIVER, 1999, 19 (04): : 263 - 264
  • [9] Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
  • [10] Burt AD, 1998, SEMIN DIAGN PATHOL, V15, P246